Skip to main content

MedImmune, Sanofi Pasteur to create and market respiratory tract illness prevention drug – Patient Daily

By August 7, 2017News
medimmune-logo

medimmune-logo

MedImmune and Sanofi Pasteur are creating and marketing MEDI8897, a drug that aims to prevent lower respiratory tract illnesses that stem from respiratory syncytial virus.

Respiratory syncytial virus, which has symptoms that are related to colds, leads the way when it comes to what gives children and infants lower respiratory tract illness.

{iframe}http://patientdaily.com/stories/511147380-medimmune-sanofi-pasteur-to-create-and-market-respiratory-tract-illness-prevention-drug{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.